Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - World Courier Australia Pty Ltd, The Hydration Pharmaceuticals Trust, Lavida Pharmaceuticals, Vita Gold Products Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to establish a national scheme for regulating therapeutic goods in Australia, aiming to protect public health and safety by ensuring the quality, efficacy, and safety of these goods. This legislation was introduced to address the need for a cohesive regulatory framework governing the manufacturing, importation, advertising, and distribution of therapeutic goods, thereby filling the gap left by previous, more fragmented state and territory-based regulations. The Act was enacted by the Parliament of Australia and its primary policy objective is to safeguard the health of the Australian public by controlling the therapeutic goods market. The Therapeutic Goods Administration (TGA) is the key regulatory body under this Act, responsible for enforcing compliance with the legislative requirements and ensuring that therapeutic goods meet the necessary standards before they are made available to consumers.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities and individuals involved in the manufacture, supply, importation, and distribution of therapeutic goods in Australia. The Act ensures that therapeutic goods available in Australia are of acceptable quality, performance, and safety by regulating their manufacture, importation, and distribution. Specifically, the Act applies to entities that hold a licence to manufacture therapeutic goods, such as the companies mentioned in the notice, ensuring they meet regulatory standards before their products can be legally supplied in the Australian market. The Act's jurisdiction is national, applying across the Commonwealth of Australia and overseen by the Therapeutic Goods Administration. While the Act broadly covers all therapeutic goods, there are exclusions, such as goods used solely for personal use, and exemptions for certain activities under specific conditions. The application of the Act can be extended or restricted through subordinate instruments, which may detail specific requirements or further define the scope of regulated activities.

Key Provisions

The main operative section in this legislative publication is Section 38 of the Therapeutic Goods Act 1989, which pertains to the grant of licences for the manufacture of therapeutic goods. Section 38 (1) stipulates that the Secretary of the Department of Health, via written notice, grants licences to individuals or entities who meet the necessary criteria for manufacturing therapeutic goods. This section serves as the legal basis for the publication of licences granted to specific companies. Section 38 (2) mandates that any licences granted under this section must be published in the Commonwealth Gazette. This transparency measure ensures that the public is aware of which entities have been authorised to manufacture therapeutic goods within Australia. Entities granted a licence under Section 38 of the Therapeutic Goods Act 1989 must adhere to stringent obligations and requirements to maintain their licensure. These entities are required to comply with all relevant regulations and standards governing the manufacture of therapeutic goods. This includes maintaining high standards of manufacturing quality, ensuring proper storage and handling of therapeutic goods, and adhering to Good Manufacturing Practice (GMP) guidelines. Furthermore, entities must regularly report to the Therapeutic Goods Administration (TGA) on their manufacturing activities, including any changes to their operations or products. Failure to comply with these obligations may result in the suspension or revocation of the licence. In the event of non-compliance with the obligations and requirements outlined in the Therapeutic Goods Act 1989, several civil and criminal consequences may apply. Section 42A of the Act outlines the penalties for manufacturing therapeutic goods without a valid licence, which includes a fine of up to 500 penalty units ($99,500) for an individual or up to 2,500 penalty units ($497,500) for a body corporate. Section 42B stipulates that any person who knowingly or recklessly manufactures therapeutic goods that do not comply with the standards set out in the Act may be subject to a fine of up to 10,000 penalty units ($1,990,000) for an individual or up to 50,000 penalty units ($9,950,000) for a body corporate. Additionally, under Section 42D, any person who contravenes a direction issued by the TGA may be liable to a fine of up to 50 penalty units ($9,950) for an individual or up to 250 penalty units ($49,750) for a body corporate. These penalties are designed to deter non-compliance and ensure the safety and efficacy of therapeutic goods available in the Australian market.